The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein. ##STR00001##

Provided are a compound represented by the following General Formula (A1-1), a method for producing the same, and the use of the compound:

##STR00001##

wherein R.sup.5 and R.sup.6 represent a hydrogen atom or an alkyl group, L.sup.1 and L.sup.2 represent an alkylene group having 1 to 6 carbon atoms, Sp.sup.a and Sp.sup.b represent a single bond or a divalent linking group, R.sup.11 and R.sup.21 represent a substituent, and v1 and w1 are an integer of 0 to 4. Further provided that a structure represented by (R.sup.11).sub.v1-benzen ring/cyclopentadiene skeleton/naphthalene ring-(R.sup.21).sub.w1 is not line-symmetrical, where “/” represents that two rings described on left and right sides of the structure are fused.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

The present invention relates to processes of preparing N-((1,2,3,4,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-iso-propyl-1H-pyrazole-3-sulfonamide and salts thereof. The present invention further relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of the NLRP3 inflammasome pathway. In particular, the component of the inflammasome pathway is a NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome. More particularly, the compounds of the present invention have the capability to modulate the NLRP3 inflammasome pathway. Further, the compounds of the present invention are suitable for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation, in particular decrease, IL-1 beta and/or IL-18 levels.

An organic light emitting display device is provided. The organic light emitting display device may include at least one light emitting part between an anode and a cathode, and the at least one light emitting part having at least one organic layer and a light emitting layer, wherein the at least one organic layer comprises a compound represented by Chemical Formula 1 or 2.

Disclosed herein are processes for preparing certain intermediates useful in the synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or a pharmaceutically acceptable salt thereof.

In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein. ##STR00001##

A method for producing tricyclo[5.2.1.0.sup.2,6]decane-2-carboxylate according to the present invention is a method for producing tricyclo[5.2.1.0.sup.2,6]decane-2-carboxylate, containing reacting tricyclo[5.2.1.0.sup.2,6]deca-3-ene in a dilute solution containing the tricyclo[5.2.1.0.sup.2,6]deca-3-ene with carbon monoxide in the presence of an acid catalyst, followed by reaction with an alcohol, wherein the dilute solution contains 100 parts by mass or more of a tricyclo[5.2.1.0.sup.2,6]decane isomer mixture based on 100 parts by mass of the tricyclo[5.2.1.0.sup.2,6]deca-3-ene, the tricyclo[5.2.1.0.sup.2,6]decane isomer mixture contains endo-tricyclo[5.2.1.0.sup.2,6]decane (Endo form of TCD) and exo-tricyclo[5.2.1.0.sup.2,6]decane (Exo form of TCD), and a constituent ratio thereof (Endo form of TCD/Exo form of TCD) is greater than 1.0.